APTBio closes near-RMB200m Series A round

The biotech company APT Bio recently announced that it has completed Series A financing round, raising nearly 200 million yuan. The leading investor for this round is Luxin Venture Capital, with participation from Guangzhou-based Funway Capital and others.

The biotech company Applied Protein Technology (APT Bio) recently announced that it has completed Series A financing round, raising nearly 200 million yuan. The leading investor for this round is Luxin Venture Capital, with participation from Guangzhou-based Funway Capital and others.

The proceeds will be mainly used for the constructions of the company’s mass spectrometry platform capacity center and supercomputer center, development of precision medical product, and expansion of domestic and overseas markets.

Established in 2004 by the Shanghai Academy of Life Sciences of the CAS, APT Bio is mainly engaged in the application of mass spectrometry technology. In terms of products, the company has established three service platforms of scientific and technological services, biomedical characterization confirmation and precision medicine.

It is one of the earliest platforms to participate in international liver and plasma projects, and has obtained CMA measurement certification, D&B certification and ISO9001 quality certification.

APT Bio has covered more than one thousand pharmaceutical companies, two thousand research institutes and hospitals at home and abroad, and have provided more than one million sample testing and project services.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/04/26/aptbio-closes-near-rmb200m-series-a-round/.

Leave a Reply

Your email address will not be published. Required fields are marked *